Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Clinigence Holdings ( (NUTX) ) just unveiled an update.
On August 22, 2025, a securities class action complaint was filed against Nutex Health Inc. in the United States District Court for the Southern District of Texas. The complaint, which follows a recent short seller report, names the company’s top executives as defendants and alleges violations of the Securities Exchange Act of 1934. Nutex Health disputes the allegations and plans to defend itself vigorously, though an adverse ruling could significantly impact its financial position or operations.
The most recent analyst rating on (NUTX) stock is a Buy with a $103.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
Spark’s Take on NUTX Stock
According to Spark, TipRanks’ AI Analyst, NUTX is a Outperform.
Nutex Health’s overall stock score reflects strong financial performance and positive earnings call sentiment, indicating robust growth and profitability. The undervaluation based on the P/E ratio further supports a positive outlook. However, technical indicators suggest caution due to weak momentum, and increased leverage poses a potential risk.
To see Spark’s full report on NUTX stock, click here.
More about Clinigence Holdings
Average Trading Volume: 252,104
Technical Sentiment Signal: Hold
Current Market Cap: $513.3M
For an in-depth examination of NUTX stock, go to TipRanks’ Overview page.